<DOC>
	<DOC>NCT01743222</DOC>
	<brief_summary>The objective is to determine the safety, tolerability and feasibility of the inguinal intralymphatic administration of expanded allogeneic adipose-derived stem cells (eASCs)</brief_summary>
	<brief_title>Intralymphatic eASC Administration in Healthy Volunteers</brief_title>
	<detailed_description>Phase I, unicentric, single blind, clinical trial with healthy volunteers to determine the feasibility of a new administration technique.</detailed_description>
	<criteria>Age between 18 and 55 both included Inform Consent Form signed Body Mass Index (BMI) between 19 and 29 kg/m2 Presence of, at least, one lymph node of 1cm in its larger diameter in each inguinal location. It has to be accessible for administration after its localization using ultrasound scan. Pregnant (positive to urine pregnancy test) or breastfeeding women. Subjects with history of any organic or psychic pathology in their records, physical exploration or any complementary test. Any relevant current pathology, including cancer, liver pathology, gastrointestinal dysfunction, renal alteration, respiratory pathology or active acute infectious problems. Chronic disorders or previous recurrent like hypertension, infections, cardiovascular, respiratory, endocrine, neurologic, hematologic, renal or liver disorders. Subjects treated four weeks before the first administration with any drug, medicinal plant or Consumer Health Care in a continue routine. It is not consider exclusion criteria a sporadic medication. The physician will study the interaction between the eASC with this medication. History of hypersensibility to drugs. Volunteers participants in other clinical trial within 4 months prior the start of the study. Blood or derivatives transfusion in 6 months before the trial. Known history of abuse of alcohol or other addictive substances(amount of alcohol allow as maximum in this trial is 0.5 liter of wine or two beers or amount in grams equivalent to this of any other alcoholic drink). Illegal drugs consumption during the month before the enrollment in the study or positive result to a drug test. Positive serology for B hepatitis virus (HbsAg), C hepatitis virus or HIV (Human Inmunodeficiency Virus). Subjects whose freedom depends on legal or administrative requirements.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>